Zolmitriptan Actavis

Zolmitriptan

Method of action: Analgesic, Antimigraine

Treatment option: Headache, Migraine

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Zolmitriptan Actavis

Zolmitriptan Actavis is a prescription-only synthetic medication specifically formulated for the acute treatment of migraine headaches. Its core active ingredient is Zolmitriptan, which belongs to the Triptan class of drugs, marking it as a specialized therapy to be used once a migraine attack has begun.

Property	Description
Active ingredient	Zolmitriptan
Form	Oral tablet (film-coated)
Pharmacological class	Selective serotonin 5-HT1B/1D receptor agonist (Triptan)
Common use	Acute migraine headaches
Origin	Synthetic tryptamine derivative

What Type of Medicine is Zolmitriptan Actavis?

Zolmitriptan Actavis is a member of the Triptan class, formally classified as a selective serotonin 5-HT1B/1D receptor agonist. This classification indicates that the drug's action is specific, modulating two particular types of serotonin receptors in the nervous system and blood vessels. Triptans are used for treating the acute phase of migraine. This approach establishes the drug's specialized role, as it is designed to directly counteract the physiological changes underlying migraine pain, unlike general analgesics.

Composition and Form: The Single Active Ingredient Product

The medicine contains Zolmitriptan as its sole active ingredient and is typically supplied for oral administration as a film-coated tablet or orally disintegrating tablet. As a single active ingredient product, its pharmacological effect derives entirely from the Zolmitriptan compound, a synthetic tryptamine derivative. Zolmitriptan is a second-generation triptan developed with characteristics intended to improve upon the properties of earlier compounds. This continuous development aims to provide reliable, efficient relief for individuals experiencing acute migraine pain.

What is the General Purpose of Zolmitriptan?

The general purpose of Zolmitriptan is to provide specific acute migraine treatment by addressing the core vascular and neural factors of an attack. It achieves this by causing cranial vasoconstriction and inhibiting the release of certain pain-inducing chemicals from the trigeminal nerve system. The Triptan class serves as a primary option for patients requiring targeted intervention for moderate to severe migraine episodes. Its specialized mechanism means it targets the underlying cause of the migraine pain, serving as a specific intervention rather than a non-selective analgesic.

Regulatory References

Triptans for Acute Migraine (NIH/NCBI)

What side effects are possible with Zolmitriptan Actavis?

Possible side effects and safety information

The safety profile of Zolmitriptan Actavis is strictly defined by regulatory authorities and organized by frequency and the body system affected. Adverse reactions are classified based on their incidence in clinical studies and official labeling.

Common and Expected Adverse Reactions

The most frequently documented adverse effects, generally categorized as common (occurring in 1 in 100 people), are typically mild and transient. These commonly involve atypical sensations (such as tingling or warmth), dizziness, and somnolence. Other common effects include a feeling of tightness, pressure, or pain in the throat, neck, or chest, as well as nausea, dry mouth, and asthenia (lack of strength). These sensations are usually non-cardiac in nature.

Serious Adverse Reactions and Safety Restrictions

Regulatory documents emphasize the risk of rare but serious adverse reactions, primarily linked to the drug's vasoconstrictive properties. These include potential coronary vasospasm, Myocardial Infarction (MI), and cerebrovascular events such as stroke or transient ischemic attack (TIA). Use is also associated with the risk of Serotonin Syndrome, particularly when combined with other serotonergic agents. Consequently, the medicine is contraindicated (prohibited) for patients with a history of ischemic heart disease, uncontrolled hypertension, or basilar/hemiplegic migraine.

Specific Safety Considerations

The safety profile includes specific limitations for certain groups. The medicine is not recommended for use in patients with moderate to severe hepatic impairment due to the significantly increased plasma concentration of zolmitriptan. Additionally, prolonged or excessive use of any acute anti-migraine medicine, including zolmitriptan, carries a risk of developing Medication Overuse Headache (MOH).

Overdose and Emergency Response

Zolmitriptan Actavis Overdose and when to seek help

Overdose with zolmitriptan may present with clinical manifestations related to excessive pharmacological activity, most commonly reported as sedation (drowsiness) in regulatory documentation following high single doses (e.g., 50 mg). The regulatory profile highlights the potential for severe effects on the cardiovascular system, including transient elevation in systemic arterial blood pressure, and risks such as coronary artery vasospasm and myocardial infarction.

Immediate medical attention is required for any suspected overdose due to the potential for severe and life-threatening symptoms. In cases of severe intoxication, regulatory guidance recommends intensive care procedures, which include establishing a patent airway, ensuring adequate oxygenation and ventilation, and monitoring and support of the cardiovascular system.

Supportive and Monitoring Requirements

There is an explicit regulatory statement that no specific antidote is known for zolmitriptan. Consequently, management is limited to symptomatic and supportive treatment.

Due to the drug's elimination half-life, patients who experience an overdose must undergo prolonged monitoring for at least 15 hours or until all symptoms and signs fully resolve. This required observation period is crucial for managing potential delayed or recurring cardiovascular instability. The regulatory information also notes that the effect of hemodialysis or peritoneal dialysis on zolmitriptan concentrations is unknown. Specific caution is advised in patients with hepatic impairment, as their overdose risk may be heightened.

Therapeutic Uses of Zolmitriptan Actavis

Zolmitriptan Actavis is a specialized, prescription medication used for the acute treatment of migraine attacks once they have already begun. The medicine is not used to prevent attacks, but is applied only for the management of the acute episodes. This therapy is relevant across domains where short-term symptom management is appropriate. Its role is to provide targeted, supportive relief when symptoms related to heightened physiological activity become difficult to tolerate.

This medicine is commonly used to help address moderate or severe throbbing headache pain that defines a migraine episode. It is applicable in situations involving recurrent or episodic manifestations, such as acute migraine episodes occurring with or without aura, and commonly used in conditions characterized by periods of heightened symptoms like menstrual migraine. This supports the management of distressing manifestations and may assist patients in coping with the severity of the episode.

It is relevant for managing symptom clusters that may become intense or disruptive, such as photophobia (intense light sensitivity), phonophobia (sensitivity to sound), and accompanying nausea or vomiting. Used as an acute intervention, this medicine contributes to the patient maintaining functional stability, which helps reduce the overall burden of symptoms and supports general well-being during symptomatic phases.

Quick Fact: Supports management of Associated Sensory Symptoms

Regulatory References

NIH MedlinePlus overview

Eligibility and Restrictions for Use

Eligibility Scope

Populations for whom use is allowed (as stated in label):

Adults (18 to 65 years of age) with an established diagnosis of acute migraine headache, with or without aura.

Populations for whom use is contraindicated:

Patients with Ischemic Coronary Artery Disease (CAD), Coronary Artery Vasospasm (Prinzmetal's angina), or Uncontrolled Hypertension.
Individuals with a history of stroke, transient ischemic attack (TIA), or specific migraines like hemiplegic or basilar migraine.
Patients with Wolff-Parkinson-White syndrome or other cardiac accessory conduction pathway disorders.
Use within 24 hours of taking another 5-HT1 agonist (triptan) or an ergotamine-containing medication.
Use concurrently with, or within two weeks of discontinuing, a Monoamine Oxidase (MAO)-A inhibitor.

Age-related eligibility rules:

Use of the oral tablet formulation is not recommended in children under 12, adolescents (12–17), or adults over 65, as safety and efficacy have not been fully established or evaluated in these age groups.

Condition-specific eligibility rules:

Patients with severe hepatic impairment must be limited to a maximum total daily dose of 5 mg per day (oral tablet).
Women who are breastfeeding are advised to avoid breastfeeding for 24 hours after treatment to minimize infant exposure.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

The interaction profile of Zolmitriptan Actavis is officially defined by its metabolic clearance and pharmacodynamic activity as a 5 -HT1 receptor agonist. Information regarding these interactions is documented by government regulatory bodies.

Formal Restrictions and Contraindications

Interaction Classification	Interacting Agents	Official Regulatory Statement
Contraindicated	Monoamine Oxidase A (MAO-A) Inhibitors	Use is strictly prohibited; MAO-A inhibition significantly increases the systemic exposure of zolmitriptan and its active metabolite.
Contraindicated	Ergot-type Medications & Other Triptans	Use is strictly prohibited due to the risk of additive vasospastic reactions. Separation of 24 hours is required before or after zolmitriptan administration.

Documented Exposure-Altering Interactions

Several medications are documented to alter the pharmacokinetic profile of zolmitriptan:

Cimetidine approximately doubles the clearance half-life and Area Under the Curve (AUC) of zolmitriptan, indicating reduced clearance and increased systemic exposure.
Propranolol increases zolmitriptan C max and AUC by 1.5-fold, a documented pharmacokinetic modification.
Oral Contraceptives increase zolmitriptan C max by 30% and AUC by 50% according to documented analysis.

Pharmacodynamic and Other Interactions

Serotonin-Reuptake Inhibitors (SSRIs/SNRIs): Co-administration is associated with documented cases of Serotonin Syndrome due to additive serotonergic effects.
St John's Wort: Concomitant use with this herbal product should be avoided due to the potential for increased undesirable effects documented in some regulatory sources.
Hepatic Impairment: Patients with moderate to severe hepatic impairment have significantly increased blood levels of zolmitriptan due to reduced clearance, which is a population-specific interaction consideration.

Mechanism of Action

How Zolmitriptan Actavis Works

Zolmitriptan Actavis is a selective serotonin 5- HT1 B/1 D receptor agonist that acts via a dual mechanism to modulate activity within the trigeminovascular system. This action is supported by the drug's metabolite, N-desmethyl-zolmitriptan, which exhibits a 2- to 6-fold higher affinity and activity on the same targets.

Targeted Cranial Vascular Tone Regulation

The drug engages 5- HT1 B receptors on arterial smooth muscle. Activating these receptors causes the vasoconstriction (narrowing) of abnormally dilated cranial blood vessels. This results in the adjustment of cranial vascular tone, reducing mechanical stress on perivascular nerve endings.

Inhibition of Neurogenic Inflammation

Zolmitriptan addresses the neural component by engaging the 5- HT1 D receptors found presynaptically on the trigeminal nerves. This agonism blocks the release of proinflammatory neuropeptides such as CGRP (Calcitonin Gene-Related Peptide). Suppressing CGRP release limits the localized neurogenic inflammation and attenuates nociceptive signal transmission.

Central Nociceptive Pathway Modulation

Zolmitriptan is designed to cross the blood-brain barrier, allowing it to modulate central nociceptive pathways. It acts on 5- HT1 B/1 D receptors in areas like the trigeminal nucleus in the brainstem, contributing to the attenuation of overall nociceptive pathway activity.

Dosage and Administration Information

Zolmitriptan Actavis is a prescription medication administered via the oral route for the acute management of a migraine attack once it has started. It is not intended for the prevention of future migraine headaches.

Official Dosing and Frequency

The recommended starting dose for the tablet formulation is 1.25 mg or 2.5 mg. The 1.25 mg dose can be achieved by manually breaking the functionally-scored 2.5 mg tablet in half. The maximum single dose is 5 mg.

If the migraine has not resolved or returns after a transient improvement, a second dose may be administered, but it must be taken at least 2 hours after the initial dose. The total dose administered in any 24-hour period must not exceed 10 mg.

Administration Requirements

Route and Preparation:

Film-coated tablets must be swallowed whole, typically with water.
Orally Disintegrating Tablets (ODTs) are placed on the tongue to dissolve and are swallowed with saliva; they should not be broken. Food intake does not significantly impact the absorption of the drug.

Population-Specific Dose Limits:

For patients with moderate or severe hepatic impairment, the recommended initial dose is 1.25 mg, and the total daily dose is restricted to a maximum of 5 mg in 24 hours.
Use in individuals over 65 years or in pediatric patients (under 18 years) is generally not recommended as safety and efficacy data for the tablet formulation have not been established for these groups.

Recent Clinical Evidence

Evidence for Acute Migraine Treatment

The core research base for the medicine is derived from multiple large-scale randomized controlled trials (RCTs) that were double-blind and compared the active compound against a placebo to monitor changes during a migraine attack. Researchers conducted these well-controlled comparative studies to explore how symptoms change in patients with episodic migraine, regardless of the presence of an aura. The key measurements examined were the proportion of individuals who achieved pain-free status or experienced reduced pain severity within two hours of administration, with research reporting observed differences in outcomes when comparing the active medicine group to the placebo group.

Research Focus on Migraine-Associated Symptoms

Research also explored the proportion of individuals who reported the resolution of accompanying symptoms, specifically nausea, photophobia (light sensitivity), and phonophobia (sound sensitivity). These outcomes are outcomes capturing phases of heightened symptom activity. Some trials described patterns where a difference was observed in the proportion of subjects achieving freedom from associated symptoms when comparing the active medicine group to the placebo group.

Evidence in Special Patient Subgroups

While initial efficacy research focused on adults, the medicine was evaluated in specific clinical trials for the treatment of acute migraine in adolescents (ages 12 to 17). Research has also explored the acute management of migraine attacks in the subgroup of women experiencing menstrual migraine. However, trials commonly excluded individuals with certain existing medical conditions, such as specific cardiovascular risk factors. Therefore, data for these groups remain insufficient, and the research provides limited insight into outcomes for these specific populations.

Long-Term Studies and Research Uncertainty

In addition to the short-term acute trials, open-label studies monitored outcomes over the treatment of multiple acute attacks with follow-up durations extending up to one year. This research contributes to understanding the patterns of the initial response over time. However, comparative evidence is limited, as few head-to-head trials exist against other established Triptan class medications. Furthermore, long-term effects are not fully established, and research provides context but not individual predictions for all patient responses.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Zolmitriptan Actavis (FAQ)

Q: How quickly do people typically expect Zolmitriptan Actavis to start working?

Studies and official product information indicate that initial improvement in headache pain may be observed relatively quickly. For the oral tablet formulation, initial response has been noted in as little as 30 to 60 minutes. Initial response for the nasal spray has been reported in clinical studies as early as 10 minutes post-dose.

Q: What is the usual duration of effect reported for Zolmitriptan Actavis?

Regulatory information reports that the medicine and its main active compound have an elimination half-life of approximately three hours. Generally, blood concentrations of the medicine are sustained for four to six hours following administration.

Q: What is the difference between Zolmitriptan Actavis and other common migraine medicines?

Zolmitriptan is a specialized medication belonging to the triptan class. Unlike general pain relievers, official documents describe its action as selectively targeting specific serotonin receptors ( 5-HT1 B/ 1D). This action is described as causing the narrowing of certain cranial blood vessels and blocking the release of inflammatory pain-inducing chemicals from the nervous system.

Q: Does taking Zolmitriptan Actavis often lead to any rebound headaches?

Prolonged or very frequent use of any acute migraine treatment, including this one, carries a risk of developing Medication Overuse Headache (MOH). This condition is sometimes referred to by patients as a 'rebound headache.' Guidelines emphasize that limiting the frequency of use is important to minimize this risk.

Q: What foods or drinks are commonly reported to interfere with how Zolmitriptan Actavis works?

Official documents state that taking the medicine with food does not significantly impact how the drug is absorbed. However, consuming alcohol may increase certain central nervous system side effects such as dizziness and drowsiness, which are also associated with the medicine itself.

Q: Are there any specific activities, like driving, that are restricted after taking Zolmitriptan Actavis?

Since Zolmitriptan Actavis can commonly cause side effects like dizziness and somnolence (drowsiness), regulatory patient information advises caution regarding activities that require mental alertness, such as driving or operating machinery, until you understand how the medicine affects you.

Q: Does Zolmitriptan Actavis affect sleep patterns?

Official reports indicate that somnolence, which is a feeling of drowsiness or sleepiness, is a commonly reported side effect in clinical trials. While it is less frequent, insomnia (trouble sleeping) has also been reported in regulatory documents.

Q: Is there a maximum number of days per month Zolmitriptan Actavis is recommended to be used?

To minimize the risk of developing Medication Overuse Headache (MOH), professional guidelines derived from clinical practice advise limiting the use of triptans, including zolmitriptan, to fewer than 10 days per month.

Q: Can Zolmitriptan Actavis be used at the same time as other headache treatments like NSAIDs?

The medicine is strictly prohibited if taken within 24 hours of another triptan or an ergot-type medicine. However, the regulatory labels do not typically require the same mandatory time interval between this medication and common nonsteroidal anti-inflammatory drugs (NSAIDs).

Q: Why is it important to take Zolmitriptan Actavis when the migraine first starts?

Official guidelines advise using the medicine to treat an acute migraine episode as soon as the headache pain begins to maximize the likelihood of achieving relief. The medicine is not approved for use during the aura phase (before the pain starts) or for preventing future migraines. Its approved use is to address the pain and associated symptoms once the acute migraine attack has started.

Q: Can Zolmitriptan Actavis cause heart-related issues in people without existing conditions?

Official regulatory documents caution that serious adverse cardiac events, such as heart attack and arrhythmia (irregular heartbeat), have been reported rarely. These events have occurred in some cases within a few hours of administration, even in patients who did not have a prior history or known heart disease.

Q: Do studies suggest Zolmitriptan Actavis helps with migraine aura, or just the pain phase?

Zolmitriptan Actavis is officially approved for the acute treatment of migraine headaches that occur with or without aura. Its approved use is to address the pain and associated symptoms once the acute migraine attack has started.

Q: Is Zolmitriptan Actavis known to cause allergic reactions?

Yes, official safety information states that the medicine is contraindicated (prohibited) for individuals with a known hypersensitivity to zolmitriptan. Hypersensitivity refers to a severe allergic reaction to the drug or any component in its formulation.

Q: Is Zolmitriptan Actavis addictive or habit-forming?

Zolmitriptan is not listed as a controlled substance in major regulatory schedules, meaning it is not considered to have a high potential for abuse or dependency like scheduled drugs. The main risk associated with frequent use is the development of Medication Overuse Headache (MOH).

Q: Do people typically experience withdrawal symptoms if they stop using Zolmitriptan Actavis?

While the medicine is not considered a controlled substance, abruptly stopping after frequent overuse can lead to Medication Overuse Headache (MOH). This condition may present with characteristics that are similar to withdrawal symptoms, frequently occurring in the morning.

Q: Are there any reported differences in effectiveness based on gender or ethnicity?

Retrospective analysis of pharmacokinetics (how the body handles the drug) showed no significant differences between certain ethnic groups, such as Japanese and Caucasian patients. However, studies noted that mean plasma concentrations were observed to be up to 1.5-fold higher in females than in males.

Q: Are there known risks associated with mixing Zolmitriptan Actavis with caffeine?

Clinical interaction studies specifically performed with caffeine found no clinically relevant differences in the pharmacokinetics (how the body absorbs, distributes, and processes the drug) of zolmitriptan or its active metabolite.

How should Zolmitriptan Actavis be stored and disposed of?

How to Store and Dispose of Zolmitriptan Actavis?

This medicine must be stored according to officially documented stability requirements to maintain its integrity.

Storage Conditions

The product should be kept at Controlled Room Temperature, which is generally between 20 C and 25 C (68 F and 77 F), with permitted temperature excursions. It must be stored away from moisture, excessive heat, and direct light, and must be kept from freezing.

For stability, the orally disintegrating tablet must remain in its sealed blister pack until the moment of administration. It must be kept in its closed original container and stored safely, out of the reach of children.

Disposal Instructions

To dispose of unused or expired medicine, follow local drug disposal regulations. Officials generally advise utilizing a medicine take-back program if one is available. If a take-back program is not accessible, official guidance suggests disposal in the household trash after mixing the medicine with an unappealing substance, such as coffee grounds, to prevent accidental consumption. The product should not be flushed down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.